Next 10 |
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
2024-04-18 16:01:51 ET Summary VKTX has reported positive data from a phase 1 trial of the oral formulation of VK2735, showing a placebo-adjusted weight loss of 3.3% at the highest dose at 28 days. There was an absence of plateauing of weight loss at 4 weeks at the higher doses, m...
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, In...
2024-04-15 16:08:10 ET Summary Given the huge and growing GLP-1 weight loss market, recent trial data from Viking Therapeutics could make it a potential acquisition target for a larger concern. While many bigger pharma names might desire entry into the huge GLP-1 weight loss marke...
2024-04-13 08:47:00 ET Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 203...
2024-04-11 13:49:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are one of the hottest investing opportunities in the stock market lately. The optimism surrounding the industry is evident in the SPDR S&P Biotech ETF’s...
2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...
2024-04-09 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We are seeing underlyi...
2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...
2024-04-09 10:00:00 ET CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the clinical or regulatory front. These relatively small ...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, In...
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 38.64% on an annualized basis producing an average annual re...
2024-04-13 08:47:00 ET Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 203...